StockNoteStockNote
Hai Duong Pharmaceutical and Medical Supplies Joint Stock Company (DHD), formerly known as Hai Hung Pharmaceutical Joint Stock Company, was established in 1982. DHD operates mainly in the field of manufacturing and trading medicines and medical supplies. The company officially came into operation under the model of a joint stock company from April 2003. DHD is managing and operating 6 production lines meeting GMP-WHO standards, 1 laboratory meeting GLP-WHO standards and 1 warehouse of finished products meeting GDP – who standards. In addition, DHD has developed a distribution system with 12 branches throughout the province and nearly 200 pharmacies spread across all areas in Hai Duong province. DHD is traded on UPCOM market from 05/05/2017.
DHD currently has a market capitalization of roughly VND 1.297 billion, placing it in the mid-cap group on the Vietnamese stock market. Its current P/E of 20,3x is 33% above its own 8-year average (15,3x), suggesting the stock is trading richer than its historical norm. P/B stands at 2,4x, 76% above its multi-year average of 1,4x. Return on equity (ROE) is at 12,7%, up from 11,7% the year before. Its debt-to-equity ratio of 0,6x is moderate, reflecting a balanced capital structure. In 2025, revenue grew 3% year-on-year while after-tax profit grew 37%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.